Evidence map›Paper›PMID 36590401›Full record

ReviewFrontiers in microbiology2022

New insights into bacterial mechanisms and potential intestinal epithelial cell therapeutic targets of inflammatory bowel disease.

Bing Liang, Changhao Wu, Chao Wang, Wenshe Sun, Wujun Chen, Xiaokun Hu, Ning Liu, Dongming Xing

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Debate on the relationship betweenFrontiers in microbiology · 2024
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Bing LiangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Changhao WuDepartment of Biochemistry and Physiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom.
Chao WangCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wenshe SunCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Wujun ChenCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Xiaokun HuIntervention Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Ning LiuCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Dongming XingCancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Affiliated Hospital of Qingdao University · CNQingdao University · CNUniversity of Surrey · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global incidence of inflammatory bowel disease (IBD) has increased rapidly in recent years, but its exact etiology remains unclear. In the past decade, IBD has been reported to be associated with dysbiosis of gut microbiota. Although not yet proven to be a cause or consequence of IBD, the common hypothesis is that at least some alterations in the microbiome are protective or pathogenic. Furthermore, intestinal epithelial cells (IECs) serve as a protective physical barrier for gut microbiota, essential for maintaining intestinal homeostasis and actively contributes to the mucosal immune system. Thus, dysregulation within the intestinal epithelium increases intestinal permeability, promotes the entry of bacteria, toxins, and macromolecules, and disrupts intestinal immune homeostasis, all of which are associated with the clinical course of IBD. This article presents a selective overview of recent studies on bacterial mechanisms that may be protective or promotive of IBD in biological models. Moreover, we summarize and discuss the recent discovery of key modulators and signaling pathways in the IECs that could serve as potential IBD therapeutic targets. Understanding the role of the IECs in the pathogenesis of IBD may help improve the understanding of the inflammatory process and the identification of potential therapeutic targets to help ameliorate this increasingly common disease.

Indexed as

bacterial mechanismsgut microbiotainflammatory bowel diseaseintestinal epithelial cells (IECs)therapeutic targets

Identifiers

PMID36590401
PMCPMC9802581
OpenAlexW4313271863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.